IN2014KN02935A - - Google Patents
Info
- Publication number
- IN2014KN02935A IN2014KN02935A IN2935KON2014A IN2014KN02935A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A IN 2935KON2014 A IN2935KON2014 A IN 2935KON2014A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A
- Authority
- IN
- India
- Prior art keywords
- 6alkyl
- hydrogen
- 6alkoxy
- proviso
- hydroxy
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150094373 Padi4 gene Proteins 0.000 abstract 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/064649 WO2014015905A1 (en) | 2012-07-26 | 2012-07-26 | 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02935A true IN2014KN02935A (en) | 2015-05-08 |
Family
ID=49996626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2935KON2014 IN2014KN02935A (en) | 2012-07-26 | 2012-07-26 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9127003B2 (en) |
| EP (1) | EP2877467B1 (en) |
| JP (1) | JP6063567B2 (en) |
| KR (1) | KR101916443B1 (en) |
| CN (1) | CN104470919B (en) |
| AU (1) | AU2012386257B2 (en) |
| BR (1) | BR112015001545B1 (en) |
| CA (1) | CA2879341C (en) |
| CY (1) | CY1118524T1 (en) |
| DK (1) | DK2877467T3 (en) |
| ES (1) | ES2609126T3 (en) |
| HR (1) | HRP20161530T1 (en) |
| HU (1) | HUE033294T2 (en) |
| IN (1) | IN2014KN02935A (en) |
| LT (1) | LT2877467T (en) |
| PL (1) | PL2877467T3 (en) |
| PT (1) | PT2877467T (en) |
| RS (1) | RS55684B1 (en) |
| RU (1) | RU2611010C2 (en) |
| SI (1) | SI2877467T1 (en) |
| SM (2) | SMT201700052T1 (en) |
| WO (1) | WO2014015905A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017024678A2 (en) * | 2015-05-21 | 2018-07-31 | Glaxosmithkline Intellectual Property Development Limited | benzoimidazole derivatives as pad4 inhibitors |
| AR107030A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 |
| AR107032A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | PAD4 BICYCLIC INHIBITORS |
| CN109071497B (en) * | 2016-02-23 | 2021-10-22 | 帕德罗科治疗公司 | PAD4 Heteroaryl Inhibitors |
| CN107188867A (en) * | 2016-03-14 | 2017-09-22 | 中国科学院天津工业生物技术研究所 | The inhibitor of arginine deiminase 4 |
| KR102398941B1 (en) * | 2016-07-27 | 2022-05-17 | 패들락 테라퓨틱스, 인코포레이티드 | covalent inhibitor of PAD4 |
| WO2018049296A1 (en) * | 2016-09-12 | 2018-03-15 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| WO2018102262A1 (en) * | 2016-12-02 | 2018-06-07 | University Of Massachusetts | Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof |
| CN108689946B (en) * | 2017-04-12 | 2022-10-18 | 中国科学院上海药物研究所 | 2-substituted sulfenyl acetamide compound and preparation method and application thereof |
| HUE067314T2 (en) * | 2017-09-22 | 2024-10-28 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| US11426412B2 (en) * | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as PRMT5 inhibitors |
| TWI762769B (en) * | 2018-02-26 | 2022-05-01 | 大陸商藥捷安康(南京)科技股份有限公司 | Peptidylarginine deiminase inhibitor and use thereof |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CA3102598A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN112566916B (en) | 2018-08-08 | 2023-10-20 | 百时美施贵宝公司 | Substituted Thienopyrroles as PAD4 Inhibitors |
| KR102825194B1 (en) * | 2018-08-08 | 2025-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted benzimidazoles as PAD4 inhibitors |
| SG11202101174RA (en) | 2018-08-08 | 2021-03-30 | Bristol Myers Squibb Co | Indole and azaindole inhibitors of pad enzymes |
| EP3833439B1 (en) * | 2018-08-08 | 2023-07-12 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
| CN109369513B (en) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | Preparation method of FBDD common molecular fragment |
| JP7212781B2 (en) | 2018-12-19 | 2023-01-25 | ディスアーム セラピューティクス， インコーポレイテッド | Inhibitors of SARM1 in combination with neuroprotective agents |
| WO2021003078A1 (en) * | 2019-07-03 | 2021-01-07 | University Of Massachusetts | Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof |
| CN112574230B (en) * | 2019-09-27 | 2022-10-28 | 药捷安康(南京)科技股份有限公司 | Peptidylarginine deiminase inhibitor and use thereof |
| WO2021158840A1 (en) * | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (en) * | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | Heterocyclic pad4 inhibitors |
| CN111265526B (en) * | 2020-04-09 | 2021-03-19 | 黑龙江中医药大学 | Medicine for treating gastric cancer and preparation method thereof |
| WO2021222353A1 (en) * | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| IL301285A (en) | 2020-09-10 | 2023-05-01 | Precirix N V | A portion of an antibody against FAP |
| WO2022059779A1 (en) | 2020-09-18 | 2022-03-24 | 大日本住友製薬株式会社 | Amine derivative |
| US11878965B2 (en) | 2020-12-22 | 2024-01-23 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202233174A (en) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | Inhibitors of peptidylarginine deiminases |
| US20250136607A1 (en) | 2021-11-15 | 2025-05-01 | Regor Pharmaceuticals, Inc. | Pad4 inhibitors and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| EP4518911A1 (en) | 2022-05-02 | 2025-03-12 | Precirix N.V. | Pre-targeting |
| CN119604287A (en) * | 2022-05-26 | 2025-03-11 | 细胞基因公司 | Heterocyclic PAD4 inhibitors |
| AU2023387505A1 (en) * | 2022-11-24 | 2025-07-10 | Helios Huaming Biopharma Co., Ltd. | Selenium containing heterocycle compounds and use thereof |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| EE03997B1 (en) | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterol metered dose inhaler |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| BR9913888A (en) * | 1998-09-18 | 2002-01-08 | Basf Ag | Compound, and, methods of inhibiting protein kinase activity, treating a patient who has a condition that is mediated by protein kinase activity and decreasing fertility in a patient |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| ATE290865T1 (en) * | 1999-10-19 | 2005-04-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| NZ519121A (en) | 1999-12-24 | 2004-05-28 | Aventis Pharma Ltd | Azaindoles useful as Syk kinase inhibitors |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| CA2544378A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
| EP1687309A1 (en) | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| FR2862971B1 (en) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
| US7429611B2 (en) | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
| WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
| US20090311217A1 (en) | 2008-05-28 | 2009-12-17 | Wyeth | 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| RU2011106786A (en) * | 2008-07-23 | 2012-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | PYRAZOLOPYRIDINKINASE INHIBITORS |
| SG174125A1 (en) * | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
-
2012
- 2012-07-26 PL PL12740581T patent/PL2877467T3/en unknown
- 2012-07-26 IN IN2935KON2014 patent/IN2014KN02935A/en unknown
- 2012-07-26 PT PT127405819T patent/PT2877467T/en unknown
- 2012-07-26 SI SI201230769A patent/SI2877467T1/en unknown
- 2012-07-26 JP JP2015523426A patent/JP6063567B2/en active Active
- 2012-07-26 BR BR112015001545-0A patent/BR112015001545B1/en active IP Right Grant
- 2012-07-26 KR KR1020157005099A patent/KR101916443B1/en active Active
- 2012-07-26 US US14/416,937 patent/US9127003B2/en active Active
- 2012-07-26 CA CA2879341A patent/CA2879341C/en active Active
- 2012-07-26 HR HRP20161530TT patent/HRP20161530T1/en unknown
- 2012-07-26 HU HUE12740581A patent/HUE033294T2/en unknown
- 2012-07-26 AU AU2012386257A patent/AU2012386257B2/en active Active
- 2012-07-26 LT LTEP12740581.9T patent/LT2877467T/en unknown
- 2012-07-26 EP EP12740581.9A patent/EP2877467B1/en active Active
- 2012-07-26 CN CN201280074868.5A patent/CN104470919B/en active Active
- 2012-07-26 DK DK12740581.9T patent/DK2877467T3/en active
- 2012-07-26 RS RS20170121A patent/RS55684B1/en unknown
- 2012-07-26 ES ES12740581.9T patent/ES2609126T3/en active Active
- 2012-07-26 WO PCT/EP2012/064649 patent/WO2014015905A1/en not_active Ceased
- 2012-07-26 SM SM20170052T patent/SMT201700052T1/en unknown
- 2012-07-26 RU RU2014152456A patent/RU2611010C2/en active
-
2015
- 2015-08-03 US US14/816,246 patent/US9518054B2/en active Active
-
2016
- 2016-11-15 US US15/352,340 patent/US9833449B2/en active Active
-
2017
- 2017-01-24 SM SM201700052T patent/SMT201700052B/en unknown
- 2017-01-27 CY CY20171100128T patent/CY1118524T1/en unknown
- 2017-11-20 US US15/817,562 patent/US10039755B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02935A (en) | ||
| BR112017024678A2 (en) | benzoimidazole derivatives as pad4 inhibitors | |
| MX2020003242A (en) | Heterocyclic compounds as pad inhibitors. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| NZ754827A (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| MY170904A (en) | Ret inhibitor | |
| MX2020003341A (en) | Imidazo-pyridine compounds as pad inhibitors. | |
| MX2015000129A (en) | Pyrimidine pyrazolyl derivatives. | |
| MX351471B (en) | Pyridinone and pyrimidinone derivatives as factor xia inhibitors. | |
| PH12014502573A1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| TN2015000245A1 (en) | Heterocyclic compound | |
| PH12014502788A1 (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | |
| MX350539B (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor. | |
| MX2014002208A (en) | Serine/threonine pak1 inhibitors. | |
| MY182082A (en) | Biheteroaryl compounds and uses thereof | |
| MD20150071A2 (en) | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of CNS and other disorders | |
| WO2014144374A3 (en) | Process for pure carbon production, compositions, and methods thereof | |
| MY178390A (en) | Inhibitors of iap | |
| MX2017010624A (en) | Cyclic amine derivative and pharmaceutical use thereof. | |
| MX2021015514A (en) | Heterocyclic compound. | |
| MX2017005423A (en) | Polyheteroaryl histone deacetylase inhibitors and their use in therapy. | |
| MX2015015614A (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS. | |
| MX2017007577A (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof. | |
| MX369345B (en) | Processes for the preparation of oxytocin analogues. | |
| MX2019010487A (en) | Cyclic amine derivative and pharmaceutical use thereof. |